All In Biotech

Drug Trial Radar · NCT02814409

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Last checked: Nov 20, 2026Latest source record: Jun 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,858 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,858

Actual

Start

Dec 15, 2016

Primary completion

Aug 31, 2023

Study completion Jan 10, 2024

Sponsor

Lead sponsor
NHS Greater Glasgow and ClydeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Glasgow; University of Edinburgh; Oxford University Hospitals NHS Trust
First posted
Jun 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The principle research question is: in patients with acute ischaemic stroke eligible for intravenous (IV) thrombolysis, is tenecteplase superior in efficacy to alteplase, based on functional outcome as assessed by modified Rankin Scale distribution at day 90?

Conditions

  • Ischemic Stroke

Interventions

  • Intravenous recombinant tissue plasminogen activator (rtPA) AlteplaseDrug

    IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion

  • Intravenous TenecteplaseDrug

    IV Tenecteplase 0.25mg/kg (max 25mg) single bolus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. modified Rankin ScaleTime frame: Day 90 (+/- 7)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth University Hospital

    Glasgow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.